3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dicke, KA; Dimopoulos, MA; Huan, SD; Jagannath, S; LeMaistre, CF; Spinolo, JA; Spitzer, G; Yau, JC; Zagars, GK; Zander, AR | 1 |
1 trial(s) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Child; Combined Modality Therapy; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Whole-Body Irradiation | 1994 |